COVID-19 Gives Gilead A Down Quarter, But Guidance Boosted By Remdesivir

 
• By Mandy Jackson

Sales were down in the second quarter to $5.07bn, primarily due to coronavirus-related impacts, but Gilead’s COVID-19 antiviral therapy remdesivir will boost revenues in the second half.

Second quarter
Gilead had $5.07bn in second quarter 2020 sales, down 10% year-over-year • Source: Shutterstock

More from Earnings

More from Business